Search Results

Pharm Country

Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities

Amarantus Bioscience Holdings, Inc. today released a letter to its shareholders announcing it has entered into a non-binding term sheet to sell the Company’s Engineered Skin Substitute (ESS).

April 27, 2022

·

7 min read

Biotech Bay

Amarantus Subsidiary Cutanogen Corporation Announces Issuance of U.S. Patent 14/299

Once approved, ESS is eligible for 12 years of market exclusivity under the BPCIA.

January 23, 2018

·

6 min read

Biotech Bay

Amarantus Subsidiary Cutanogen Corporation Announces Issuance of U.S. Patent 14/299

Once approved, ESS is eligible for 12 years of market exclusivity under the BPCIA.

January 23, 2018

·

6 min read

Pharm Country

Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products

Amarantus Bioscience Holdings, Inc. announced that it has completed an exclusive worldwide sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products, a diversified cannabidiol -focused health sciences company.

January 6, 2020

·

6 min read

Deals

Cambrex Corporation Acquires Cutanogen Corporation

February 3, 2006

·

7 min read

Policy

Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics

Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa

November 25, 2019

·

5 min read

Deals

Amarantus Provides Recapitalization Update to Shareholders

Amarantus Bioscience Holdings, Inc. released a letter to its shareholders following the announcement of the binding term sheet to license the Company’s therapeutics subsidiaries’ technologies to Emerald Organic Products, an emerging CBD-focused health sciences company, and other recent events

November 19, 2019

·

14 min read

Drug Development

Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET

Topline results expected before the end of Q1/2020

November 14, 2019

·

10 min read

Business

Amarantus Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products

Amarantus Bioscience Holdings, Inc. announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc., a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels.

October 27, 2019

·

6 min read

Drug Development

Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings

Emerald Organic Products, Inc. and Amarantus Bioscience Holdings today announced a principal agreement for the exclusive, worldwide license of several cutting-edge treatments, including Phase 3-ready therapies for ADHD and skin regeneration.

October 25, 2019

·

6 min read